NCT04414163 2026-04-21
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
ImmuneOncia Therapeutics Inc.
Phase 2 Active not recruiting
ImmuneOncia Therapeutics Inc.
ImmuneOncia Therapeutics Inc.
Sorrento Therapeutics, Inc.
ImmuneOncia Therapeutics Inc.